Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Will Buy Generics Firm

by Rick Mullin
May 25, 2009 | A version of this story appeared in Volume 87, Issue 21

Novartis has agreed to acquire EBEWE Pharma, an Austria-based producer of generic injectable drugs, for $1.2 billion in cash. The deal will broaden the global market for EBEWE's oncology medicines—Novartis' Sandoz unit is the world's second-largest generics company. EBEWE's product line includes generic versions of key cancer drugs, including paclitaxel, epirubicin, methotrexate, and oxaliplatin. EBEWE's neurological products business is not part of the deal.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.